Patents by Inventor Christian KOESSL

Christian KOESSL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20240150480
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Application
    Filed: November 14, 2023
    Publication date: May 9, 2024
    Inventors: Klaus-Peter KUENKELE, Timothy FENN, Juan Manuel GARCIA-MARTINEZ, Jason HO, Christian KOESSL, Saurabh SEN, Vladimir VOYNOV, Andreas WERNITZNIG, Ertan ERYILMAZ, Rajkumar GANESAN, Abdulsalam SHAABAN
  • TRAILR2 CDH17 binding molecules for the treatment of cancer
    Patent number: 11851495
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20210095038
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Application
    Filed: October 30, 2020
    Publication date: April 1, 2021
    Inventors: Klaus-Peter KUENKELE, Timothy FENN, Juan Manuel GARCIA-MARTINEZ, Jason HO, Christian KOESSL, Saurabh SEN, Vladimir VOYNOV, Andreas WERNITZNIG, Ertan ERYILMAZ, Rajkumar GANESAN, Abdulsalam SHAABAN
  • TRAILR2 CDH17 binding molecules for the treatment of cancer
    Patent number: 10858438
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20180179287
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Klaus-Peter KUENKELE, Timothy FENN, Juan Manuel GARCIA-MARTINEZ, Jason HO, Christian KOESSL, Saurabh SEN, Vladimir VOYNOV, Andreas WERNITZNIG